Signaling pathways
-
BA8818 TolebrutinibSummary: Tolebrutinib (SAR442168) is a potent, selective, orally active and blood-brain barrier-crossing inhibitor of Bruton's tyrosine kinase with values of 0.4 and 0.7 nM in RamosB cells and HMC microglia, respectively. - BA8819 OrelabrutinibSummary: Orelabrutinib (ICP-022) is a potent, orally active, irreversible Bruton tyrosine kinase inhibitor with potential antitumor activity.
- BA8820 NX-2127Summary: NX-2127 is an orally effective inhibitor that induces the degradation of mutations in cells.
- BA8821 Ibrutinib-biotinSummary: Ibrutinib-biotin is a probe consisting of Ibrutinib attached to biotin via a long linker.
- BA8822 MT-802Summary: MT-802 is a ligand-based, degrading agent.
- BA8823 VecabrutinibSummary: Vecabrutinib (SNS-062) is an inhibitor.
- BA8824 SJF620Summary: The SJF620 is a PROTAC that is connected by a ligand to a ligand.
- BA8825 Ibrutinib-MPEASummary: Ibrutinib-MPEA is a derivative of Ibrutinib.
- BA8826 PCI-33380Summary: A selective, irreversible inhibitor (fluorescent probe) of Bruton's tyrosine kinase.
- BA8827 TL-895Summary: TL-895 is a potent, orally active, ATP-competitive, highly selective irreversible inhibitor with summed values of 1.5 nM and 11.9 nM, respectively.